Don Dizon is a medical oncologist specializing in the care of women's cancers. He trained in medical oncology at Memorial Sloan-Kettering Cancer Center (MSKCC) where he was also on the faculty in the Developmental Therapeutics section and Gynecologic Oncology Disease Management Team at MSKCC until 2003.

Between 2003 and 2009 he was the director of medical oncology at the Program in Women's Oncology at Women & Infants Hospital of Rhode Island and an Associate Professor in Obstetrics & Gynecology and Medicine at the Warren Alpert School of Medicine at Brown University, where he also founded the Center for Sexuality, Intimacy, and Fertility for women with cancer (CSIF)- the first and only program of its kind in Rhode Island.

In July 2012, he transferred his clinical practice to MGH, where he founded and is director of the new Oncology Sexual Health Clinic at the MGH Cancer Center. He is now the Clinical Co-Director of Gynecologic Oncology at the Massachusetts General Hospital Cancer Center and an Associate Professor of Medicine at Harvard Medical School.

In addition to his clinical duties, he is a co-chair of the Cervical Cancer Task Force for the NCI Gynecologic Cancer Steering Committee. He is also prolific on social media and maintains online columns for ASCO and for the journal, The Oncologist.  He is the chair of the social media working group for ASCO and was named the inaugural chair of the Digital Engagement Committee for the Southwest Oncology Group (SWOG).

All rights reserved © 2018
HQ/ONCO/18/0003 | Preparation date: October 2018
Reporting of suspected adverse events is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.
To ensure correct adverse event reporting, healthcare professionals are encouraged to use the appropriate website for their national authority.